OZEMPIC® 0.25mg

Description

Name: OZEMPIC® 0.25mg
Manufacturer: Novo Nordisk
Active Substance(s): SEMAGLUTIDE
Strength: 0,25mg
Pack Size: 1 pen, 4 disposable NovoFine® Plus needles (4 Doses)

OZEMPIC® 0.25mg is a once-weekly injectable prescription medicine used to improve blood sugar control in adults with type 2 diabetes mellitus. It contains semaglutide, a GLP-1 receptor agonist that works by enhancing insulin secretion, suppressing glucagon secretion, and slowing gastric emptying. The 0.25 mg dose is typically used as a starting dose for the first four weeks to allow the body to adjust to treatment and reduce gastrointestinal side effects. OZEMPIC® is not insulin and should not be used to treat type 1 diabetes or diabetic ketoacidosis. It is available only with a doctor’s prescription and must be used under medical supervision.

• Weekly Dosing: Administered once weekly, regardless of meals or time of day.
  
• GLP-1 Receptor Agonist: Helps the pancreas produce more insulin and lowers glucagon when glucose is high.
• Starter Dose: 0.25 mg weekly for four weeks, followed by an increase to 0.5 mg as maintenance or further to 1 mg if necessary.

OZEMPIC® 0.25mg is available in a prefilled dial-a-dose pen, which contains 1.5 mL of solution to deliver 0.25 mg or 0.5 mg doses. Each pack includes one pen and six NovoFine® Plus needles. The pen is intended for subcutaneous use and should be used with a new sterile needle for each injection.

Active Ingredient:

• Semaglutide (rys): 1.34 mg/mL (Total: 2 mg per pen)
  

Inactive Ingredients:

• Dibasic sodium phosphate dihydrate
• Propylene glycol
• Phenol
• Hydrochloric acid and sodium hydroxide (for pH adjustment)
• Water for injections
  

The abbreviation “rys” indicates recombinant yeast-based production of semaglutide through genetic engineering.

OZEMPIC® is indicated for the treatment of adults with type 2 diabetes mellitus to improve glycaemic control when diet and exercise alone are insufficient. It may be used alone or in combination with other antidiabetic medications such as metformin, sulfonylureas, TZDs, or insulin.

Contraindications:

• Hypersensitivity to semaglutide or any component
• Type 1 diabetes or diabetic ketoacidosis
• Pregnancy or intent to become pregnant within 2 months
• Breastfeeding
• Severe gastrointestinal disease or history of pancreatitis
  

Common Side Effects:

• Nausea, vomiting, diarrhoea
• Decreased appetite, indigestion, constipation
• Headache, dizziness, fatigue
• Hypoglycaemia, especially when combined with sulfonylureas or insulin
• Injection site reactions (pain, bruising, rash)
• Upper respiratory tract infections
  

Serious Side Effects:

• Pancreatitis (severe abdominal pain radiating to the back)
• Gallbladder disease (e.g. gallstones)
• Allergic reactions (rash, swelling, difficulty breathing)

OZEMPIC® must be injected subcutaneously into the abdomen, thigh, or upper arm, and should never be injected intravenously or intramuscularly. Patients must receive training from a healthcare provider before self-injection.

Administration:

• Start with 0.25 mg once weekly for 4 weeks
• After 4 weeks, increase to 0.5 mg once weekly
• Administer on the same day each week; may change the day if ≥3 days have passed since the last dose
• Use a new needle for each injection
• Rotate injection sites to reduce the risk of lipodystrophy
  

If a dose is missed:

• Administer within 5 days of the missed dose
• If more than 5 days have passed, skip and resume on the next scheduled day
  

Storage:

• Before opening: Store pens in a refrigerator (2°C to 8°C). Do not freeze.
• After opening: Store at room temperature (below 30°C) or in the refrigerator for up to 6 weeks
• Protect from heat, light, and freezing
• Discard pens after 6 weeks, even if solution remains
• Do not use if the solution is cloudy, coloured, or contains particles
  

Proper storage, handling, and dose escalation are essential to maximize therapeutic effect and minimize gastrointestinal side effects. Always follow healthcare provider instructions for safe and effective use.

Warning! The product is intended solely for professional use in a medical environment and under professional supervision. The product is supplied to medical professionals who specialize in aesthetic medicine (plastic surgery, facial treatments) and work under individual medical licenses as aestheticians or in dedicated clinics. Unprofessional use by individuals without a medical background may lead to severe adverse effects and health harm.